| Age, median (interquartile range), y |
67 (5.1) |
68 (9.2) |
| Male |
98 (80.3) |
92 (74.8) |
| Female |
24 (19.7) |
31 (25.2) |
| American Society of Anesthesiologists classification |
|
|
| 1 |
12 (10.2) |
14 (11.7) |
| 2 |
80 (67.8) |
83 (69.2) |
| 3 |
25 (21.2) |
23 (19.2) |
| 4 |
1 (0.8) |
0 (0.0) |
| Charlson Comorbidity Index score |
|
|
| 0 |
81 (66.4) |
80 (65.0) |
| 1 |
22 (18.0) |
21 (17.1) |
| 2 |
9 (7.4) |
10 (8.1) |
| 3 |
7 (5.7) |
7 (5.7) |
| 4 |
2 (1.6) |
2 (1.6) |
| 5 |
0 |
2 (1.6) |
| 6 |
1 (0.8) |
1 (0.8) |
| 7 |
0 |
0 |
| Tumor type |
|
|
| Adenocarcinoma |
105 (86.1) |
114 (92.3) |
| Squamous cell carcinoma |
12 (9.8) |
7 (5.7) |
| Other |
5 (4.1) |
2 (1.6) |
| Tumor location |
|
|
| Intrathoracic midesophagus |
6 (4.9) |
3 (2.4) |
| Intrathoracic distal esophagus |
105 (86.1) |
106 (86.2) |
| Gastroesophageal junction |
11 (9.0) |
14 (11.4) |
| cT stage |
|
|
| T1 |
2 (1.6) |
4 (3.2) |
| T2 |
23 (18.9) |
19 (15.4) |
| T3 |
68 (55.7) |
65 (52.8) |
| T4 |
1 (0.8) |
2 (1.6) |
| Tx |
28 (23.0) |
33 (26.8) |
| cN stage |
|
|
| N0 |
53 (43.4) |
60 (48.8) |
| N1 |
45 (36.9) |
39 (31.7) |
| N2 |
16 (13.1) |
19 (15.4) |
| N3 |
3 (2.5) |
1 (0.8) |
| N+ |
3 (2.5) |
3 (2.4) |
| Nx |
2 (1.6) |
1 (0.8) |
| Neoadjuvant treatment |
|
|
| Yes |
|
|
| Chemoradiotherapy |
118 (96.7) |
117 (95.1) |
| Chemotherapy |
2 (1.6) |
3 (2.4) |
| None |
2 (1.6) |
3 (2.4) |
| Operation type |
|
|
| Total minimally invasive esophagectomy |
97 (79.5) |
100 (81.3) |
| Hybrid minimally invasive esophagectomy |
25 (20.5) |
23 (18.7) |
| Configuration of anastomosis |
|
|
| End to end |
3 (2.5) |
46 (37.4) |
| End to side |
42 (34.4) |
2 (1.6) |
| Side to side |
77 (63.1) |
75 (61.0) |
| Anastomosis technique |
|
|
| Handsewn |
4 (3.3) |
108 (87.8) |
| Stapled |
118 (96.7) |
15 (12.2) |
